Zevra Therapeutics, Inc.
ZVRA · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | – | $482,620 | $405,176 | $447,614 |
| - Cash | $54,439 | $47,712 | $37,340 | $33,785 |
| + Debt | $62,276 | $62,276 | $61,837 | $60,296 |
| Enterprise Value | – | $497,184 | $429,673 | $474,125 |
| Revenue | $26,063 | $25,881 | $20,401 | $12,043 |
| % Growth | 0.7% | 26.9% | 69.4% | – |
| Gross Profit | $24,510 | $13,502 | $19,056 | $10,677 |
| % Margin | 94% | 52.2% | 93.4% | 88.7% |
| EBITDA | $1,466 | $80,566 | $1,701 | -$16,526 |
| % Margin | 5.6% | 311.3% | 8.3% | -137.2% |
| Net Income | -$1,410 | $74,707 | -$3,099 | -$35,739 |
| % Margin | -5.4% | 288.7% | -15.2% | -296.8% |
| EPS Diluted | -0.01 | 1.364 | -0.057 | -0.67 |
| % Growth | -100.7% | 2,479.9% | 91.4% | – |
| Operating Cash Flow | $4,709 | -$3,601 | -$8,222 | -$16,250 |
| Capital Expenditures | -$554 | -$213 | -$99 | $0 |
| Free Cash Flow | $4,155 | -$3,814 | -$8,321 | -$16,250 |